Skip to content

The effects of Fermentable Oligo-, Di-, Monosaccharides, and polyols (FODMAPs) diets on esophageal and gastric function in patients with gastroesophageal reflux disease

The effects of Fermentable Oligo-, Di-, Monosaccharides, and polyols (FODMAPs) diets on esophageal and gastric function in patients with gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220903002
Enrollment
20
Registered
2022-09-03
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease FODMAPs, GERD, Gastric emptying, Gastric accommodation

Interventions

High FODMAPs food which nutrition component and ingradient controlled ,Low FODMAPs diet which nutrition component and ingradient controlled
High FODMAPs diet,Low FODMAPs diet

Sponsors

Faculty of Medicine, Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis Gastroesophageal reflux disease by symptom for within 3 months 2. Age 18-70 yr 3. Underwent the EGD within 6 months 4. Have a symptom of GERD by clinical heartburn and/or acid regurgitation 5. Diagnosis GERD with under medication trial for 1-2 months before enrollment

Exclusion criteria

Exclusion criteria: 1. Hx of abdominal surgery except appendectomy and cesarean section 2. current gastric or liver cancer 3. Inflammatory bowel disease) 4. Irritable bowel syndrome) 5. Chronic constipation or abnormal bowel movement 6. Chronic liver disease/Chronic kidney disease 7. Abnormal finding of Esophagogastroduodenoscopy e.g pyloric stenosis 8. Helicobacter pylori infection 9. Esophageal motility disease; Achalasia, EGJ outflow obstruction, Diffuse esophageal spasm, Jackhammer esophagus, Absent peristalsis 10. Concurrent treatment with medication which may interfere the interpretation e.g. proton pump inhibitors, potassium competitive acid blockers, H2 blockers, prokinetics, selective serotonin reuptake inhibitors, antispasmodics, prebiotics, probiotics, antibiotics 11. Uncontrolled psychiatry disease 12. No consent

Design outcomes

Primary

MeasureTime frame
TLESRs 1 day pH monitoring

Secondary

MeasureTime frame
Gastric emptying, Gastric accommodation 1 day SPECT CT, Gastric emptying time

Countries

Thailand

Contacts

Public ContactPiyakorn Poonyam

Faculty of medicine chulalongkorn university

piyakorn@g.swu.ac.th0861296573

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026